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AFTER MHC-MATCHED ALLOGRAFTING, HOST-DERIVED LANGERHANS
CELLS (LCS) PERSIST IN SKIN AND CUTANEOUS LYMPH NODES IN THE
STEADY-STATE AND ARE THE TARGETS OF DLI-MEDIATED ALLORE-
SPONSE
Durakovic, N.; Bezak, K.B.; Skarica, M.; Fuchs, E.J.; Luznik, L.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Balti-
more, MD.
The mechanisms that govern T cell-mediated alloresponses in
the post-transplant setting, particularly T cell-dendritic cell (DC)
interactions, are critical for developing strategies to augment their
antitumor effects and limit toxicity such as GVHD. We hypothe-
size that kinetics of DC reconstitution and the number of host DCs
persisting in various lymphoid tissues after alloBMT may differ
and if characterized, may be relevant in guiding T cell al-
loresponses following transplant. To analyze DC reconstitution
in the MHC-matched setting, we used a B6Ly 5.2 (H2b;
CD45.1)3C3H.SW (H2b; CD45.2) model that differs in ex-
pression of the CD45 marker on host and donor hematopoietic
tissues. We found that the donor to host DC turnover is rapid with
near full conversion to donor DC chimerism in the spleen and
mesenteric lymph nodes but not in the cutaneous lymph nodes
(CLNs). The dominant residual host DC population in LNs is
characterized by the low expression of CD8 but high expression
of DEC-205 and gp40 (Ep-CAM), the proﬁle completely consis-
tent with the phenotype of LCs. We reproducibly detected residual
host-derived LCs in the chimeras CLNs for at least 6 months after
alloBMT and found them to constitutively express an activated
phenotype. Levels of expression of the costimulatory molecules,
CD80, CD40, and especially CD86 on host-derived LCs was
actually higher in comparison to donor-derived LCs. The skin
origin of host-derived DCs in LNs was conﬁrmed by analysis of
CD11c that migrate out of ex vivo cultured epidermal sheets.
Because the majority of the CD11c was of host origin, this
suggests that alloresponse against minor histocompatibility anti-
gens is not sufﬁcient enough to cause LC replacement. The per-
sistence of residual host LCs after alloBMT prompted us to de-
termine whether they serve as the target of the DLI-mediated
alloresponse. Administration of DLI 3 weeks after conditioning
resulted in the decrease of residual host-derived LCs in the CLNs
and recruitment of donor derived LCs to the skin. Our data
suggest the following: (a) After myeloablative conditioning and
transplantation of MHC-matched marrow, there is a rapid replace-
ment of secondary lymphoid organs with donor marrow-derived
DCs but that the signiﬁcant amount of skin DCs are of host origin;
(b) during steady-state conditions after alloBMT, host-derived
LCs bearing an activated phenotype are continuously present in
the CLNs; and (c) host-derived LCs are the targets of the DLI-
mediated alloresponse.
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IN VITRO RAPAMYCIN AND COSTIMULATION GENERATES TH1/TC1 OR
TH2/TC2 CENTRAL MEMORY EFFECTORS: DIFFERENTIAL REGULATION
BY IN VIVO RAPAMYCIN AFTER ALLOGENEIC BMT
Fowler, D.H.; Foley, J.; Jung, U. Experimental Transplantation and
Immunology Branch, NCI, Bethesda, MD.
Rapamycin (rapa) inhibition of GVHD is associated with Th2/
Tc2 polarization. We evaluated (a) whether rapa directly regulates
cytokine polarity independent of antigen-presenting-cells (APC)
and (b) whether rapa modulates effector Th1/Tc1 and Th2/Tc2
responses. To evaluate aim (a), T cells were costimulated in IL-4 or
IL-12 containing media. Surprisingly, Th1/Tc1 differentiation
proceeded in rapa (10 micromolar; 10-fold expansion over 6 days).
IL-2 and IFN-g secretion was preserved with no increase in IL-4,
IL-5, IL-10, or IL-13; fas ligand cytolysis was modestly reduced.
Th2/Tc2 differentiation also proceeded in rapa, with similar 10-
fold expansion, maintenance of type II cytokines, and partial pres-
ervation of granule cytolysis. Rapa-generated Th1, Tc1, Th2, and
Tc2 cells were CD44CD62L, had increased expansion to al-
loantigen (B6-into-CB6F1 BMT), and maintained cytokine polar-
ity in vivo. Rapa thus does not directly modulate cytokine polarity
and can be used to generate Th1/Tc1 and Th2/Tc2 cells of central
memory phenotype that possess enhanced capacity for T1 or T2
polarization post-BMT. To evaluate aim (b), rapa-generated T
cells were studied after allogeneic BMT with or without rapa
therapy. Congenic donor Th1/Tc1 cells (CD45.1) and Th2/Tc2
cells (CD90.1) were used in cell-mixing experiments to evaluate
effector T-cell cross-regulation. Rapa-generated Th2/Tc2 cells
potently inhibited Th1/Tc1 cell number and cytokine secretion;
this Th2/Tc2 shift was fully preserved with rapa therapy. Rapa-
generated Th1/Tc1 cells potently inhibited Th2/Tc2 cell number
and function post-BMT; however, this Th1/Tc1 shift was com-
pletely abrogated by rapa therapy ( 90% reduction in Th1/Tc1
number and function [IL-2 and IFN-g secretion]. Given the in-
hibitory role of rapa on APC function, we hypothesized that rapa
polarizes cytokine production through APC modulation. To eval-
uate this hypothesis, CB6F1 dendritic cells (DCs) were generated
in vitro. Such F1 DCs were immune competent, because their
adoptive transfer after syngeneic BMT and Th1/Tc1 cell transfer
induced graft-versus-host reaction (allospeciﬁc Th1/Tc1 cell
IFN-g secretion). However, transfer of F1 DC in the setting of
rapamycin therapy did not yield allospeciﬁc Th1/Tc1 cell re-
sponses post-BMT. In conclusion, the Th2/Tc2 polarization asso-
ciated with rapa therapy is mediated indirectly, most likely through
APC modulation that preferentially inhibits Th1/Tc1 cells.
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ALLOGENEIC B CELL RESPONSE TO H-Y MINOR HISTOCOMPATIBILITY
ANTIGENS AFTER DONOR LYMPHOCYTE INFUSION CORRELATES WITH
DISEASE RESPONSE
Miklos, D.B.1; Miller, K.1; Kim, H.T.2; Lee, S.J.2; Alyea, E.P.2; Cutler,
C.2; Antin, J.H.2; Soiffer, R.J.2; Ritz, J.2 1. Stanford University
Medical Center, Stanford, CA; 2. Dana-Farber Cancer Institute, Bos-
ton, MA.
Donor lymphocyte infusion (DLI) can induce remission in many
patients who relapse after allogeneic hematopoietic stem cell trans-
plantation (HSCT). We have previously demonstrated that male
HSCT patients with female donors frequently develop high-titer
antibody responses to H-Y antigens that correlate with disease
remission. We sought to determine whether allogeneic B-cell re-
sponses develop after DLI. We expressed 5 recombinant H-Y
proteins (DBY, UTY, ZFY, RPS4Y, and EIF1AY) and developed
sensitive ELISA to quantify the development of speciﬁc anti-HY
antibodies. First, we studied prophylactic DLI. Twenty-six patients
who received T-cell-depleted HSCT followed 5–7 months later by
prophylactic CD8 depleted DLI were tested for H-Y antibodies
pre-DLI and 6–12 months after DLI. No H-Y antibodies were
detected in any of the pre-DLI serum samples. However, all 6 male
HSCT patients with female donors (F3M HSCT) developed
high-titer antibodies against at least 1 H-Y antigen after DLI. In
contrast, only 1/20 of the other donor/recipient gender combina-
tions (4 M3M, 8 F3F, 8 M3F) resulted in H-Y antibody (P 
.005). Thus, mHA disparity is required for the development of
allogeneic B cell responses after DLI. This robust development of
H-Y antibody in 6/6 F3M patients who received TCD transplan-
tation and prophylactic DLI was signiﬁcantly greater than in the
3/9 who developed H-Y antibodies after receiving the same TCD
HSCT without DLI (P  .03). This suggests that DLI augments
allogeneic B-cell responses after T-cell-depleted HSCT. To ex-
amine the effects of therapeutic DLI, we studied 24 F3M HSCT
patients who relapsed 60 days to 15 years (median 704 days) after
transplant and subsequently received either unmanipulated DLI or
CD8-depleted DLI. Only 2/24 had any H-Y antibody at the time
of relapse. After DLI, 17/24 (71%) developed antibody to at least
1 H-Y antigen, and this correlated with complete remission after
DLI (P  .001). Disease progression continued in all 7 patients
who did not develop H-Y antibodies, but 15 of 17 patients who
developed H-Y antibodies also attained complete remission. H-Y
antibodies developed rapidly and were detected as early as 26 days
after DLI. Complete remission was attained with similar frequen-
cies after both CD8 depleted DLI (7/12) and unmanipulated DLI
(8/12). In summary, H-Y antibodies frequently develop in male
patients after infusion of female donor lymphocytes, and this allo-
geneic B cell response correlates with clinical response to DLI.
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